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CLINICAL SCALES, CRITERIA AND TOOLS
Translation and validation into Brazilian 
Portuguese of the Spastic Paraplegia Rating 
Scale (SPRS)
Tradução e validação da escala de classificação de paraplegia espástica (SPRS) para a 
versão brasileira
Katiane R. Servelhere, Ingrid Faber, Ana Carolina Coan, Marcondes França Junior
Hereditary spastic paraplegias (HSP) are a heteroge-
neous group of heredodegenerative disorders, characterized 
by progressive and retrograde degeneration of the cortico-
spinal tracts in the spinal cord1,2,3,4.  To date, there are more 
than 70 genetic types described5. The core clinical features 
of HSP are slowly progressive spasticity and weakness of the 
lower limbs. In pure HSP, patients present essentially with 
a spastic gait, but they may also have urinary incontinence 
and deep sensory abnormalities in the legs. In contrast, pa-
tients with complicated forms of HSP have other associated 
manifestations, such as dementia, peripheral neuropathy, 
parkinsonism and ataxia.
Patients with HSP often have a slow disease progression, 
but the clinical course may be different even for patients with 
the same genetic background. Therefore, it is important to ap-
ply standardized and validated instruments to assess disease 
severity in the long term. In addition, clinical trials directed 
towards HSP will need robust clinical scales to assess the ef-
ficacy of treatments. In this scenario, the German Network for 
Hereditary Movement Disorders (GeNeMove) developed and 
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ABSTRACT
Hereditary spastic paraplegias (HSP) are characterized by progressive lower limb weakness and spasticity. There are no validated 
instruments to quantify disease severity in Portuguese. Objective: To translate and validate the Spastic Paraplegia Rating Scale (SPRS) into 
Brazilian-Portuguese. Method: Two experienced and English-fluent neurologists translated SPRS into Portuguese, creating SPRS-BR. We then 
assessed inter and intra-rater reliability of this version using coefficients of correlation and variability in a cohort of 30 patients. Results: 
Mean age of patients and disease duration were 47.7 ± 10.5 and 17.0 ± 10.6 years, respectively. Twenty-one had pure HSP and SPG4 was the 
most frequent genotype. Mean Rankin and SPRS-BR scores were 2.2 ± 0.9 and 19.9 ± 9.9, respectively. Mean intra and inter-rater correlation 
coefficients of SPRS-BR scores were 0.951 and 0.934, whereas coefficients of variation were 11.5% (inter-rater) and 9.9% (intra-rater). 
Cronbach’s alpha for the whole SPRS-BR scale was 0.873. Conclusion: SPRS-BR is a useful, reliable and valid clinical instrument.
Keywords: spastic paraplegia, hereditary; scales; tranlating.
ReSumo
As paraparesias espásticas hereditárias (PEH) apresentam progressiva espasticidade e fraqueza dos membros inferiores. Não existem 
escalas validadas em língua portuguesa para quantificar a gravidade da doença. Objetivo: Traduzir e validar para o português do Brasil 
a Spastic Paraplegia Rating Scale (SPRS). Método: Dois neurologistas experientes em neurogenética e fluentes em inglês traduziram a 
SPRS para o português, criando a SPRS-BR. Em seguida, checamos a reprodutibilidade da escala usando coeficientes de correlação e 
variabilidade em um grupo de 30 pacientes. Resultados: As médias de idade e duração de doença foram de 47,7 ± 10,5 e 17,0 ± 10,6 anos, 
respectivamente.  Vinte e um eram portadores da forma pura de PEH, sendo que SPG4 foi o genótipo mais frequente. A pontuação das 
escalas Rankin e SPRS-BR foi, respectivamente, 2,2 ± 0,9 e 19,9 ± 9,9. Os coeficientes de correlação inter e intraexaminador da SPRS-BR 
foram 0,934 e 0,951, enquanto que os coeficientes de variação foram de 11,5% (interexaminador) e 9,9% (intraexaminador). O coeficiente 
alfa de Cronbach’s para a escala SPRS-BR foi de 0.873. Conclusão: A SPRS-BR é uma escala útil clinicamente, fácil de aplicar e que 
apresentou boa reprodutibilidade e validade.
Palavras-chave: paraplegia espástica hereditária; escalas; tradução.
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validated a scale that rates functional impairment, focusing 
on the key features of pure spastic paraplegias: the Spastic 
Paraplegia Rating Scale (SPRS). This tool is easy to use in the 
clinic, and presented good reliability and validity as a mea-
sure of disease severity6. Several studies employed SPRS in 
cohorts of patients with HSP3,7,8,9,10. Taking into account that 
there are no such instruments available in our language, 
we designed this study to validate the Brazilian Portuguese 
version of SPRS. We believe that such an instrument would 
optimize the clinical care of our patients not only with HSP 
but also with other chronic myelopathies.
meThod
Translation of SPRS and cultural adaptation
SPRS has thirteen items that include: walking distance 
without pause; gait quality; maximum gait speed; climbing 
stars; arising from chair; spasticity of hip adductor and knee 
flexion muscles; weakness of hip abduction and foot dorsi-
flexion; contracture of lower limbs; pain related to spasticity 
and bladder and bowel function. Each item has a score rang-
ing from 0 to 4, where 0 represents no dysfunction and 4 rep-
resents most severe dysfunction. The score result is calculat-
ed by adding single scores of each of the 13 items6. Therefore, 
SPRS total score varies between 0 (no dysfunction) and 52 
(most severe dysfunction).
Two board-certified Brazilian neurologists, fluent in 
English and experienced in the care of patients with heredi-
tary spastic paraplegia translated SPRS into Portuguese. This 
process resulted in two forward translations: versions 1 and 2. 
The translators discussed the translations and the consen-
sus resulted in a reconciled version (version 3). Subsequently, 
another researcher fluent in English back translated the rec-
onciled version into the English language, resulting in version 
4 of the scale. Versions 3 and 4 were then assessed by the au-
thors, through the comparison with the original text for the 
correction of discrepancies and creation of a consensus final 
version (SPRS-BR) - Appendix.
We then assessed inter and intra-rater reliability of 
SPRS-BR. This was done through the evaluation of 30 adult 
patients with clinical and/or molecular confirmation of HSP 
in two stages, by 2 experienced researchers, and using co-
efficients of correlations and variability. For each patient, 
we also applied the Rankin scale11. This was done to investi-
gate whether SPRS-BR scores correlate with this measure of 
independence for activities of daily living.
The study was approved by our institution ethics commit-
tee. Written informed consent was obtained from all patients 
prior to any study-related procedure.
Statistical analyses
For each patient, we recorded data on age, age at on-
set, disease duration, gender, SPRS and Rankin total scores, 
inheritance pattern, genotype, need for walking assistive de-
vices and time interval between examinations. These data 
are shown with descriptive statistics: categorical variables 
expressed as relative frequency (%) and numerical variables 
expressed as mean ± SD.
To assess the internal consistency of SPRS-BR, we used 
the Cronbach’s alpha coefficient, and considered values high-
er than 0.8 indicating good consistency.
To assess intra and inter-rater reliability of SPRS-BR, 
we performed 2 different analyses. We first used Spearman coef-
ficients to assess the correlation of SPRS-BR scores performed 
by the same evaluator in 2 distinct days (intra-rater) and by 
2 different evaluators in the same day (inter-rater). We then ex-
plored intra and inter-rater variability of SPRS-BR scores using 
coefficients of variation (CV). These were calculated as
SD = ∑√ (x1 - x2)
2
2n , Mean = ∑
x1 + x2
2n  and CV(%) = 100X SDMean . , 
where n is the number of patients (30), x1 and x2 are the 
scores obtained for different examiners (or the same exam-
iner in different days).
The statistical analyses were performed using software 
systat 12.0.
ReSulTS
We evaluated 30 adult patients with pure and compli-
cated HSP that were regularly followed at the neurogenetics 
clinic at UNICAMP. Sixteen patients were able to walk un-
assisted, 10 needed some walking assistive device (Canadian 
crutches, canes and/or walkers) and 4 patients were wheel-
chair bound and did not walk at all. Mutations in the SPAST 
gene were identified in 40% of HSP patients in this cohort. 
Further demographic and genetic data of the patients includ-
ed in this study are shown in Table 1.
Application of SPRS-BR took around 10–15 minutes and 
did not require any special equipment. The examiners 1 (KRS) 
and 2 (IF) performed the first evaluation separately, but in the 
same day. Then, examiner 1 performed an additional evalua-
tion after 31 days on average, to assess intra-rater reliability. 
Taking into account that HSP are slowly progressive disorders, 
we believe that no significant score change due to true disease 
worsening is supposed to take place in this short time frame.
Patients with complicated HSP had higher SPRS-BR scores 
than patients with pure HSP (27.4 ± 8.9 vs 16.7 ± 8.6, p = 0.0064). 
SPRS-BR scores obtained from examiner 1 at 2 different mo-
ments were highly correlated (Spearman p = 0.95); the same 
finding took place regarding SPRS-BR scores obtained from ex-
aminers 1 and 2 (Spearman p = 0.93) – Table 2. Intra-rater and 
inter-rater CV were 9.9% and 11.5%, respectively. Cronbach’s 
alpha for all questions was 0.87, thus indicating a good inter-
nal consistency. When patients were categorized according to 
Rankin scores, we were able to see that SPRS-BR scores clearly 
increased in parallel to Rankin scores (Figure).
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diSCuSSion
SPRS is an instrument easy to apply that takes no longer 
than 10–15 minutes to complete. It is suitable for use both 
for research and for routine care of patients with HSP. Our 
Brazilian Portuguese version of the scale – SPRS-BR – present-
ed good internal consistency, as well as intra and inter-rater 
reliability. Furthermore, it presented a clear correlation with 
Table 1. Demographic and clinical data of patients with 
hereditary spastic paraplegia included in this study.
Gender (M/F) 14/16
Phenotype
Pure (%) 21 (70%)
Complicated (%) 9 (30%)
Inheritance pattern
Autosomal dominant (%) 21 (70%)





Age (mean ± SD, years) 47.7 ± 10.5
Age at onset (mean ± SD, years ) 30.8 ± 14.4
Disease duration (mean ± SD, years ) 17.0 ± 10.6
Interval between examinations (mean ± SD, days) 31.4 ± 23.8
Rankin Score (mean ± SD ) 2.2 ± 0.9
SPRS total score (mean ± SD) 19.9 ± 9.9
SPRS: spatic paraplegia retina scale.
Table 2. Correlation analyses using Spearman coefficients 
showing inter-rater (first column) and intra-rater (second 
column) reliability.















the Rankin score, which is a standard measure of functional 
impairment for neurological patients. Taken together, these 
data suggest that SPRS-BR is a robust instrument for clinical 
use that will help neurologists involved in the care not only 
of patients with HSP but also of patients with other forms of 
chronic myelopathies, such as tropical spastic paraplegia and 
subacute combined degeneration of the spinal cord12,13.
In this validation study, we included patients with different 
genotypes presenting both pure and complicated phenotypes of 
HSP. We opted to do so in order to assess the whole phenotypic 
spectrum of HSP. Overall, patients with complicated HSP had 
higher SPRS-BR scores than pure HSP, which is in agreement 
with the more widespread neurological impairment they have. 
In terms of clinical application, SPRS-BR was easy to perform 
both for pure and complicated HSP. In a similar way, when we 
considered only complicated HSP, the parameters of intra and 
inter-rater reliability were both high (p = 0.962 and 0.912, respec-
tively). We must acknowledge, however, that only adults were 
evaluated in this study (older than 18 years), so that we cannot 
ascertain that SPRS-BR is adequate and reliable to use in chil-
dren with HSP. This needs to be investigated in future studies.
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(1) distância que caminha sem pausa
De acordo com a história, dispositivos auxiliares são 
permitidos
0: Normal, ilimitada
1: Cansaço anormal devido à espasticidade após mais 
de 500m
2: Caminha menos de 500m
3: Caminha menos de 10m
4: Incapaz de andar
(2) Qualidade da marcha
É solicitado ao paciente andar o mais rápido possível uma 
distância de 10 metros, incluindo uma volta
0: Normal
1: Rigidez leve, correr ainda é possível
2: Marcha claramente espástica, interferindo no correr
3: Marcha espástica, com necessidade de dispositivos 
auxiliares
4: Incapaz de andar uma distância de 10 metros mesmo 
com apoio máximo
(3) Velocidade máxima da marcha
Tempo cronometrado para uma distância de 10 metros, in-
cluindo uma volta.
0: Normal
1: Levemente reduzida(10m: ≥ 5s)
2: Moderadamente reduzida(10m: ≥ 10s)
3: Gravemente reduzida(10m: ≥ 20s)
4: Incapaz de andar uma distância de 10m ou tempo ≥ 40s
(4) Subir escadas
Subir 5 degraus–volta/giro–descer 5 degraus
0: Normal: não necessita apoio do corrimão
1: Incapacidade leve: necessita de apoio intermitente 
do corrimão
2: Incapacidade moderada: necessita de apoio contínuo 
do corrimão
3: Incapacidade grave: necessita de apoio/suporte de out-
ra pessoa ou dispositivo adicional para realizar a tarefa
4: Incapaz de subir escadas
(5) Velocidade para subir escadas
Tempo cronometrado para subir 5 degraus – volta/giro – 
descer 5 degraus
0: Normal
1: Levemente reduzida(≥ 5s para realizar a tarefa)
2: Moderadamente reduzida(≥ 10s para realizar a tarefa)
3: Gravemente reduzida(≥ 20s para realizar a tarefa)
4: Incapaz de subir escadas
(6) levantar-se da cadeira
O paciente tenta se levantar de uma cadeira de madeira ou 
metal e encosto reto, com os braços cruzados sobre o peito
0: Normal
1: Lento ou pode necessitar de mais de uma tentativa.
2: Levanta-se com apoio dos braços da cadeira.
3: Tende a cair para trás e pode necessitar de mais de uma 
tentativa, mas pode se levantar sem ajuda.
4: Incapaz de se levantar sem ajuda.
(7) espasticidade -músculos adutores do quadril 
(escala modificada de Ashworth)
Pontue o lado mais afetado
0: Tônus muscular normal
1: Leve aumento de tônus muscular, manifestado por 
tensão momentânea
2: Aumento mais marcante do tônus muscular durante 
a maior parte da amplitude de movimento
3: Considerável aumento do tônus muscular – movi-
mento passível é difícil
4: Membro fixo em adução
(8) espasticidade -flexão do joelho (escala 
modificada de Ashworth)
Pontue o lado mais afetado
0: Tônus muscular normal
1: Leve aumento de tônus muscular, manifestado por 
tensão momentânea
2: Aumento mais marcante do tônus muscular durante 
a maior parte da amplitude de movimento
3: Considerável aumento do tônus muscular – movi-
mento passível é difícil
4: Membro fixo emflexão ou extensão
(9) Fraqueza–abdução do quadril (medical 
Research Council 1976)
0: Sem fraqueza
1: Fraqueza leve (4/5)
2: Fraqueza moderada (3/5)
3: Fraqueza grave (1-2/5)
4: Plegia (0/5)
(10) Fraqueza–dorsiflexão do pé (medical 
Research Council 1976)
0: Sem fraqueza
1: Fraqueza leve (4/5)
2: Fraqueza moderada (3/5)
3: Fraqueza grave (1-2/5)
4: Plegia (0/5)
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(11) Contraturas dos membros inferiores
Pontue na posição supina
− Extensão de quadril: coluna lombar e coxas tocam a su-
perfície. Abdução de quadril: abdução até um ângulo >60° 
entre as pernas é possível
− Extensão de joelhos: coxas e panturrilhas tocam a 
superfície.
− Extensão dorsal do tornozelo: > 10° é possível. Pronação 
do tornozelo : > 10° é possível
0: Sem contraturas
1: Leve, posição anormal não fixa de uma articulação 
(unilateral ou bilateral)
2: Contratura fixa de uma articulação (unilateral ou bilateral)
3: Contratura fixa de duas articulações (unilateral ou 
bilateral)
4: Contratura fixa de mais de duas articulações (unilat-
eral ou bilateral)
(12) dor secundária a sintomas relacionados à 
paraplegia espástica
0: Sem dor
1: Presente em ≤ 50% do dia enquanto acordado E in-
tensidade 0 - 3 pontos na escala visual analógica
2: Presente em ≤ 50% do dia enquanto acordado E in-
tensidade 4 - 10 pontos na escala visual analógica
3: Presente em > 50% do dia enquanto acordado E inten-
sidade 0 - 3 pontos na escala visual analógica
4: Presente em > 50% do dia enquanto acordado E in-
tensidade 4 - 10 pontos na escala visual analógica
(13) Função vesical e intestinal
0: Função vesical e intestinal normais
1: Urgência urinária ou fecal (dificuldade de chegar ao 
banheiro a tempo)
2: Urge incontinência rara e leve (sem necessidade de fralda)
3: Urge incontinência moderada (necessidade de fralda 
ou cateter quando fora de casa)
4: Uso de cateter ou fralda permanentes 
